CN102510752B - 含有大环内酯类免疫抑制药物的新颖的药物组合物 - Google Patents

含有大环内酯类免疫抑制药物的新颖的药物组合物 Download PDF

Info

Publication number
CN102510752B
CN102510752B CN201080042067.1A CN201080042067A CN102510752B CN 102510752 B CN102510752 B CN 102510752B CN 201080042067 A CN201080042067 A CN 201080042067A CN 102510752 B CN102510752 B CN 102510752B
Authority
CN
China
Prior art keywords
tacrolimus
pharmaceutical composition
skin
microemulsion
amphiphilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080042067.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102510752A (zh
Inventor
亚历山德拉·赛宾·巴贝尔·戈贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bai Yi Pharmaceutical Co ltd
Original Assignee
Novaliq GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq GmbH filed Critical Novaliq GmbH
Publication of CN102510752A publication Critical patent/CN102510752A/zh
Application granted granted Critical
Publication of CN102510752B publication Critical patent/CN102510752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • G01N2001/4061—Solvent extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201080042067.1A 2009-10-08 2010-10-07 含有大环内酯类免疫抑制药物的新颖的药物组合物 Active CN102510752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09012724.2 2009-10-08
EP09012724A EP2308468A1 (en) 2009-10-08 2009-10-08 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
PCT/EP2010/064965 WO2011042485A1 (en) 2009-10-08 2010-10-07 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug

Publications (2)

Publication Number Publication Date
CN102510752A CN102510752A (zh) 2012-06-20
CN102510752B true CN102510752B (zh) 2015-08-05

Family

ID=41435414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080042067.1A Active CN102510752B (zh) 2009-10-08 2010-10-07 含有大环内酯类免疫抑制药物的新颖的药物组合物

Country Status (12)

Country Link
US (1) US8574562B2 (cg-RX-API-DMAC10.html)
EP (2) EP2308468A1 (cg-RX-API-DMAC10.html)
JP (1) JP5764792B2 (cg-RX-API-DMAC10.html)
KR (1) KR101790257B1 (cg-RX-API-DMAC10.html)
CN (1) CN102510752B (cg-RX-API-DMAC10.html)
AU (1) AU2010305404B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012007332B1 (cg-RX-API-DMAC10.html)
CA (1) CA2774720C (cg-RX-API-DMAC10.html)
ES (1) ES2552803T3 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN01559A (cg-RX-API-DMAC10.html)
MX (1) MX2012003800A (cg-RX-API-DMAC10.html)
WO (1) WO2011042485A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310770A (zh) * 2016-06-03 2019-02-05 埃维克辛公司 包含多不饱和酮和钙调磷酸酶抑制剂的联合疗法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
GEP20166459B (en) * 2011-06-23 2016-04-11 Santen Pharmaceutical Co Ltd Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
CN103830178B (zh) * 2014-03-18 2017-01-11 深圳劲创生物技术有限公司 一种蒜氨酸微乳及其制备方法和应用
WO2017025588A1 (en) * 2015-08-11 2017-02-16 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
CN109069418B (zh) 2016-04-04 2026-03-13 Mc2疗法有限公司 包含他克莫司的局部组合物
CN106074386A (zh) * 2016-08-31 2016-11-09 佛山市弘泰药物研发有限公司 一种依维莫司自微乳制剂及其制备方法
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
EP4093396B1 (en) * 2020-01-22 2025-12-10 Bausch Health Ireland Limited Topical compositions comprising a macrolide immunosuppressant
TWI769745B (zh) * 2021-03-19 2022-07-01 國泰醫療財團法人國泰綜合醫院 醫藥組成物與製藥用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
BE1030538B1 (nl) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan
KR102727647B1 (ko) * 2023-11-28 2024-11-08 장병모 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2315216A (en) * 1993-10-05 1998-01-28 Ciba Geigy Ag Microemulsion preconcentrates comprising FK 506
US20030143250A1 (en) * 1988-09-16 2003-07-31 Birgit Hauer Pharmaceutical compositions comprising cyclosporins
WO2006062334A1 (en) * 2004-12-06 2006-06-15 Hanmi Pharm. Co., Ltd. Oral micro-emulsion composition comprising tacrolimus
WO2006123354A2 (en) * 2005-02-02 2006-11-23 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
EP1929996A2 (en) * 2004-11-09 2008-06-11 Novagali Pharma SA Ophthalmic emulsions containing an immunosuppressive agent
US20090074786A1 (en) * 2005-02-09 2009-03-19 Macusight, Inc. Formulations for treating ocular diseases and conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DK0786986T3 (da) * 1994-10-26 2002-04-29 Novartis Ag Anvendelse af en umættet fedtalkohol
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
EP1441696B1 (en) * 2001-11-01 2010-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and composition for dry eye treatment
MXPA04005783A (es) * 2001-12-14 2004-09-13 Jagotec Ag Formulacion farmaceutica que comprende ciclosporina y uso de la misma.
AU2005263551B2 (en) * 2004-07-16 2009-04-09 Novartis Ag Use of a steroid for enhancement of skin permeability
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143250A1 (en) * 1988-09-16 2003-07-31 Birgit Hauer Pharmaceutical compositions comprising cyclosporins
GB2315216A (en) * 1993-10-05 1998-01-28 Ciba Geigy Ag Microemulsion preconcentrates comprising FK 506
EP1929996A2 (en) * 2004-11-09 2008-06-11 Novagali Pharma SA Ophthalmic emulsions containing an immunosuppressive agent
WO2006062334A1 (en) * 2004-12-06 2006-06-15 Hanmi Pharm. Co., Ltd. Oral micro-emulsion composition comprising tacrolimus
WO2006123354A2 (en) * 2005-02-02 2006-11-23 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
US20090074786A1 (en) * 2005-02-09 2009-03-19 Macusight, Inc. Formulations for treating ocular diseases and conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310770A (zh) * 2016-06-03 2019-02-05 埃维克辛公司 包含多不饱和酮和钙调磷酸酶抑制剂的联合疗法

Also Published As

Publication number Publication date
CA2774720C (en) 2017-05-23
US8574562B2 (en) 2013-11-05
BR112012007332A2 (pt) 2016-10-04
KR20120093865A (ko) 2012-08-23
CN102510752A (zh) 2012-06-20
EP2485714A1 (en) 2012-08-15
EP2485714B1 (en) 2015-09-09
CA2774720A1 (en) 2011-04-14
IN2012DN01559A (cg-RX-API-DMAC10.html) 2015-06-05
MX2012003800A (es) 2012-06-28
AU2010305404B2 (en) 2015-04-02
AU2010305404A1 (en) 2012-03-08
ES2552803T3 (es) 2015-12-02
KR101790257B1 (ko) 2017-10-26
JP5764792B2 (ja) 2015-08-19
JP2013507337A (ja) 2013-03-04
US20120184511A1 (en) 2012-07-19
WO2011042485A1 (en) 2011-04-14
EP2308468A1 (en) 2011-04-13
BR112012007332B1 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
JP5764792B2 (ja) マクロライド免疫抑制剤を含む新規な医薬組成物
JP6901421B2 (ja) 半フッ化アルカンを基礎にした局所薬学的組成物
JP2020183427A (ja) 局所製剤
JPH05507903A (ja) シクロスポリンの局所用処方
KR102891680B1 (ko) Jak 저해제 및 라우레스-4를 함유하는 국소 제형
JP2016183202A (ja) ミニエマルションを形成させるための方法および生理活性薬剤を送達するためのその使用
CZ302649B6 (cs) Farmaceutická formulace zahrnující cyklosporin a její použití
Saadallah et al. Binary ethosomal gel for enhanced transdermal delivery of tazarotene: Development, refinement, in vitro evaluation, and skin penetration investigations
JP2024544404A (ja) Ｓｈｒ０３０２の安定な製剤
CN108348456A (zh) 异维甲酸制剂及其用途和方法
HK1167102A (en) Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
RU2538680C2 (ru) Фармацевтическая композиция для лечения атопического дерматита и способ ее получения
CN118660693A (zh) Shr0302的稳定制剂
HK40002180A (en) Topical pharmaceutical composition based on semifluorinated alkanes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1167102

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: NEUBERT REINHARD

Free format text: FORMER OWNER: NOVALIQ GMBH

Effective date: 20150709

Free format text: FORMER OWNER: WOHLRAB JOHANNES

Effective date: 20150709

Owner name: SKINOMICS GMBH

Free format text: FORMER OWNER: NEUBERT REINHARD

Effective date: 20150709

Owner name: WOHLRAB JOHANNES

Effective date: 20150709

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150709

Address after: Halle (Sall)

Applicant after: Novaliq GmbH

Address before: Halle (Sall)

Applicant before: Nehad Neubert

Applicant before: Jonas Horabi

Effective date of registration: 20150709

Address after: Halle (Sall)

Applicant after: Nehad Neubert

Applicant after: Jonas Horabi

Address before: Heidelberg

Applicant before: Novaliq GmbH

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180614

Address after: German SEK

Patentee after: Bai Yi Pharmaceutical Co.,Ltd.

Address before: Halle (Sall)

Patentee before: Novaliq GmbH